Pharma firm Algeta Q3 loss smaller than forecast

01:25 EST 6 Nov 2013 | Reuters

OSLO, Nov 6 (Reuters) - Norway's Algeta, which has developed a novel prostate cancer drug with Germany's Bayer , reported a smaller-than-expected loss on Wednesday and raised slightly its estimates for 2013 revenues and marketing costs.

Original Article: Pharma firm Algeta Q3 loss smaller than forecast

NEXT ARTICLE

More From BioPortfolio on "Pharma firm Algeta Q3 loss smaller than forecast"

Search BioPortfolio:
Advertisement

Relevant Topics

Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.  Cancer sometimes begins in one part of the body before spre...

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement

Searches Linking to this Story